Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
Active, not recruiting · NCT04394858 · Registry updated 2026-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, paraganglioma, pheochromocytoma, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-09-10 | NCT04394858 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
163 results · Page 1 of 7
Research sites
Swipe the table sideways for more columns.